Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

mankind pharma block deal: Block Deal: Hema CIPEF prone to promote round 1% stake in Mankind Pharma

0



Mumbai: Hema CIPEF (I), an affiliate of the US-based Capital Group, is prone to promote a 0.9% stake in Mankind Pharma on Wednesday via block offers, in accordance with the time period sheet issued by bankers IIFL Securities and Kotak Securities. Hema CIPEF is providing to promote 37 lakh shares at a ground value of Rs 2,061 per share, which is a 2% low cost to Tuesday’s closing value of Rs 2,102.50 on the NSE. The deal on the ground value is valued at Rs 763 crore.

Capital Group held a 2.22% stake within the firm as on March 31, 2024. In December final 12 months, Capital Group divested a 3.14% stake in Mankind Pharma.

Mankind Pharma launched its maiden public provide in April of final 12 months. The Rs 4,326-crore preliminary share sale of Mankind Pharma was subscribed 15.32 instances. The IPO was listed on Might 5 of final 12 months at a premium of 31% and has rallied 48% since then.

Leave a Reply

Your email address will not be published. Required fields are marked *